CN105593222B - 用于亲和色谱法和用于延长治疗剂的半衰期的化合物 - Google Patents
用于亲和色谱法和用于延长治疗剂的半衰期的化合物 Download PDFInfo
- Publication number
- CN105593222B CN105593222B CN201480054551.4A CN201480054551A CN105593222B CN 105593222 B CN105593222 B CN 105593222B CN 201480054551 A CN201480054551 A CN 201480054551A CN 105593222 B CN105593222 B CN 105593222B
- Authority
- CN
- China
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- heteroaryl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 C*CC(CCC1)CCC1C1CC*(CNC2CC(**)CC2)CCC1 Chemical compound C*CC(CCC1)CCC1C1CC*(CNC2CC(**)CC2)CCC1 0.000 description 1
- JDMDMHLXEDXMAA-UHFFFAOYSA-N Cc(cc(cc1)C(N(CC2)CCC2=[O]C(NC(C=CC2)=CC2C(NCCOCCOCCN)=C)=O)=O)c1-c1nc(cccc2)c2[nH]1 Chemical compound Cc(cc(cc1)C(N(CC2)CCC2=[O]C(NC(C=CC2)=CC2C(NCCOCCOCCN)=C)=O)=O)c1-c1nc(cccc2)c2[nH]1 JDMDMHLXEDXMAA-UHFFFAOYSA-N 0.000 description 1
- NTAXZHZAQFHTMT-UHFFFAOYSA-N NCCOCCOCCCNC(c(cc1CC2NC22)ccc1N=C2c1ccccc1)=O Chemical compound NCCOCCOCCCNC(c(cc1CC2NC22)ccc1N=C2c1ccccc1)=O NTAXZHZAQFHTMT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361885146P | 2013-10-01 | 2013-10-01 | |
| US61/885,146 | 2013-10-01 | ||
| US201462025994P | 2014-07-17 | 2014-07-17 | |
| US62/025,994 | 2014-07-17 | ||
| PCT/IB2014/064998 WO2015049651A1 (en) | 2013-10-01 | 2014-10-01 | Compounds for affinity chromatography and for extending the half-life of a therapeutic agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105593222A CN105593222A (zh) | 2016-05-18 |
| CN105593222B true CN105593222B (zh) | 2018-02-09 |
Family
ID=51743521
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480054551.4A Expired - Fee Related CN105593222B (zh) | 2013-10-01 | 2014-10-01 | 用于亲和色谱法和用于延长治疗剂的半衰期的化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9809558B2 (enExample) |
| EP (1) | EP3052483B1 (enExample) |
| JP (1) | JP2016534984A (enExample) |
| KR (1) | KR20160060660A (enExample) |
| CN (1) | CN105593222B (enExample) |
| AU (1) | AU2014330781B2 (enExample) |
| BR (1) | BR112016007371A2 (enExample) |
| CA (1) | CA2925862A1 (enExample) |
| ES (1) | ES2721098T3 (enExample) |
| RU (1) | RU2016117052A (enExample) |
| SG (1) | SG11201601870VA (enExample) |
| WO (1) | WO2015049651A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10697982B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies |
| US10697983B2 (en) | 2015-09-08 | 2020-06-30 | Merck Patent Gmbh | Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies |
| US20170066839A1 (en) * | 2015-09-08 | 2017-03-09 | Merck Patent Gmbh | Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies |
| JPWO2018181738A1 (ja) * | 2017-03-30 | 2020-02-13 | 日立化成株式会社 | 分離材 |
| CN112996801A (zh) * | 2018-11-26 | 2021-06-18 | 北卡罗来纳州大学 | 用于捕获宿主细胞蛋白的肽配体 |
| CN112996811B (zh) | 2018-12-21 | 2022-11-22 | 江苏恒瑞医药股份有限公司 | 双特异性蛋白 |
| MX2022006865A (es) | 2019-12-06 | 2022-07-11 | Vertex Pharma | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. |
| DK4347031T3 (da) | 2021-06-04 | 2025-12-01 | Vertex Pharma | N-(hydroxyalkyl-(hetero)aryl)-tetrahydrofuran-carboxamider som modulatorer af natriumkanaler |
| JP2024525160A (ja) | 2021-06-18 | 2024-07-10 | アリゴス セラピューティクス インコーポレイテッド | Ｐｄ－ｌ１を標的とするための方法及び組成物 |
| TW202328139A (zh) | 2021-12-16 | 2023-07-16 | 美商艾利格斯醫療公司 | 用於靶向ｐｄ－ｌ１之方法及組成物 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012736A1 (en) * | 2002-08-02 | 2004-02-12 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
| WO2012020080A2 (en) * | 2010-08-12 | 2012-02-16 | Graffinity Pharmaceuticals Gmbh | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II |
| CN103154018A (zh) * | 2010-08-03 | 2013-06-12 | 葛雷菲尼迪制药有限公司 | 用于通过亲和色谱法的抗体和Fc-融合蛋白纯化的配体 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH187973A4 (de) * | 1973-02-09 | 1977-03-31 | Hoechst Ag | Verfahren zum optischen Aufhellen von Textilmaterialien |
| US4722896A (en) | 1981-01-26 | 1988-02-02 | The Beth Israel Hospital Association | Method for affinity purification of hybridoma antibodies |
| US5849874A (en) | 1991-07-12 | 1998-12-15 | Gist-Brocades, N.V. | Process for the purification of serum albumin |
| JP2825755B2 (ja) * | 1993-04-07 | 1998-11-18 | 大塚製薬株式会社 | ピペリジン誘導体を有効成分とする末梢血管拡張剤および新規ピペリジン誘導体 |
| AU692237B2 (en) * | 1994-02-03 | 1998-06-04 | Picower Institute For Medical Research, The | Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis |
| GB9914825D0 (en) * | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
| TR200103147T1 (tr) | 1999-12-27 | 2002-06-21 | Japan Tobacco Inc. | Kaynaşık halkalı bileşikler ve bunların ilaç olarak kullanımı. |
| DE10139416A1 (de) * | 2001-08-17 | 2003-03-06 | Aventis Pharma Gmbh | Aminoalkyl substituierte aromatische Bicyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| CA2481334A1 (en) | 2002-04-01 | 2003-10-16 | Anthony C. Stevens | Tissue-specific endothelial membrane proteins |
| US7777051B2 (en) | 2003-05-13 | 2010-08-17 | Icagen, Inc. | Asymmetric benzimidazoles and related compounds as potassium channel modulators |
| WO2007056155A1 (en) | 2005-11-03 | 2007-05-18 | Chembridge Research Laboratories, Inc. | Heterocyclic compounds as tyrosine kinase modulators |
| HUE052816T2 (hu) | 2009-07-31 | 2021-05-28 | Ascendis Pharma As | Biológiailag lebontható polietilénglikol bázisú vízoldható hidrogélek |
| WO2011048018A1 (en) * | 2009-10-19 | 2011-04-28 | Boehringer Ingelheim International Gmbh | Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use |
| WO2012140647A2 (en) | 2011-04-11 | 2012-10-18 | Yeda Research And Development Co. Ltd | Albumin binding probes and drug conjugates thereof |
| UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
| EP2752426A1 (en) | 2013-01-03 | 2014-07-09 | Covagen AG | Human serum albumin binding compounds and fusion proteins thereof |
-
2014
- 2014-10-01 RU RU2016117052A patent/RU2016117052A/ru not_active Application Discontinuation
- 2014-10-01 AU AU2014330781A patent/AU2014330781B2/en not_active Ceased
- 2014-10-01 JP JP2016519325A patent/JP2016534984A/ja active Pending
- 2014-10-01 KR KR1020167008267A patent/KR20160060660A/ko not_active Withdrawn
- 2014-10-01 CN CN201480054551.4A patent/CN105593222B/zh not_active Expired - Fee Related
- 2014-10-01 EP EP14786355.9A patent/EP3052483B1/en active Active
- 2014-10-01 CA CA2925862A patent/CA2925862A1/en not_active Abandoned
- 2014-10-01 US US15/026,725 patent/US9809558B2/en not_active Expired - Fee Related
- 2014-10-01 SG SG11201601870VA patent/SG11201601870VA/en unknown
- 2014-10-01 ES ES14786355T patent/ES2721098T3/es active Active
- 2014-10-01 WO PCT/IB2014/064998 patent/WO2015049651A1/en not_active Ceased
- 2014-10-01 BR BR112016007371A patent/BR112016007371A2/pt not_active Application Discontinuation
-
2017
- 2017-09-07 US US15/698,020 patent/US9938243B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004012736A1 (en) * | 2002-08-02 | 2004-02-12 | Genesoft Pharmaceuticals, Inc. | Biaryl compounds having anti-infective activity |
| CN103154018A (zh) * | 2010-08-03 | 2013-06-12 | 葛雷菲尼迪制药有限公司 | 用于通过亲和色谱法的抗体和Fc-融合蛋白纯化的配体 |
| WO2012020080A2 (en) * | 2010-08-12 | 2012-02-16 | Graffinity Pharmaceuticals Gmbh | LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2015049651A1 (en) | 2015-04-09 |
| SG11201601870VA (en) | 2016-04-28 |
| BR112016007371A2 (pt) | 2017-08-01 |
| JP2016534984A (ja) | 2016-11-10 |
| AU2014330781B2 (en) | 2017-05-04 |
| RU2016117052A3 (enExample) | 2018-06-27 |
| CN105593222A (zh) | 2016-05-18 |
| RU2016117052A (ru) | 2017-11-10 |
| ES2721098T3 (es) | 2019-07-26 |
| EP3052483B1 (en) | 2019-02-06 |
| CA2925862A1 (en) | 2015-04-09 |
| US9809558B2 (en) | 2017-11-07 |
| EP3052483A1 (en) | 2016-08-10 |
| AU2014330781A1 (en) | 2016-04-07 |
| US20160221962A1 (en) | 2016-08-04 |
| US20170369448A1 (en) | 2017-12-28 |
| KR20160060660A (ko) | 2016-05-30 |
| US9938243B2 (en) | 2018-04-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105593222B (zh) | 用于亲和色谱法和用于延长治疗剂的半衰期的化合物 | |
| US10662261B2 (en) | Chelator and use thereof | |
| CN103154018B (zh) | 用于通过亲和色谱法的抗体和Fc-融合蛋白纯化的配体 | |
| JP2013500291A (ja) | タンパク質及びペプチドと結合する特定の充填剤、並びに、それを用いた分離方法 | |
| JPH10506987A (ja) | クロマトグラフ用樹脂およびその使用方法 | |
| BR102012018861A2 (pt) | Substrato,método de tratar uma amostra compreendendo pelo menos uma substância biológica com substrato e método para separar pelo menos uma substância de uma amostra líquida | |
| WO2015041218A1 (ja) | 新規抗体精製方法及びそれから得られる抗体（Ｎｏｖｅｌ Ａｎｔｉｂｏｄｙ Ｐｕｒｉｆｉｃａｔｉｏｎ Ｍｅｔｈｏｄ ａｎｄ Ａｎｔｉｂｏｄｙ ｏｂｔａｉｎｅｄ ｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（Ｎｏｖｅｌ Ａｎｔｉｂｏｄｙ Ｐｕｒｉｆｉｃａｔｉｏｎ ｍｅｔｈｏｄ ｕｓｉｎｇ Ｃａｔｉｏｎ Ｅｘｃｈａｎｇｅｒ ａｎｄ Ａｎｔｉｂｏｄｙ ｏｂｔａｉｎｅｄ ｔｈｅｒｅｆｒｏｍ） | |
| CN109790202B (zh) | 环肽、亲和层析载体、标记抗体、抗体药物复合体及药物制剂 | |
| JP4750035B2 (ja) | 光切断型リンカーを利用したリガンド固定化固相担体 | |
| AU2024230594A1 (en) | Photoswitchable compounds and affinity ligands, and their use for the optical control of affinity matrices | |
| JP2001527090A (ja) | アルブミンを結合する方法およびその方法で使用すべき手段 | |
| US20080093301A1 (en) | Disubstituted Cucurbituril-Bonded Silica Gel | |
| CN103923217A (zh) | 6-氨基己酸纤维素酯及其合成方法和应用 | |
| KR102843184B1 (ko) | 다이머 펩타이드-인지질 콘쥬게이트를 위한 최적화 과정 | |
| US20060014735A1 (en) | Use of urea variants as affinity ligands | |
| Nazzal et al. | Fmoc Solid-Phase FIT-PNA Synthesis—Manual and Automated Methodologies | |
| CN114933629A (zh) | 一种基于巯基-烯基叠氮偶联反应的多肽或蛋白质定向修饰方法 | |
| GB2637134A (en) | Collagen related peptide | |
| JP2019058885A (ja) | 吸着材及び標的物質の精製方法 | |
| WO2025133607A1 (en) | Collagen related peptide | |
| CN101171077A (zh) | 纤维蛋白原的亲和吸附剂 | |
| BR112021011717A2 (pt) | Substrato funcionalizado por ligante, método para a preparação do substrato funcionalizado por ligante, e, uso de um substrato funcionalizado por ligante | |
| BR112021011717B1 (pt) | Substrato funcionalizado por ligante, método para a preparação do substrato funcionalizado por ligante, e, uso de um substrato funcionalizado por ligante |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180209 Termination date: 20191001 |